Adagio Medical Holdings ( (ADGM) ) has provided an announcement.
On February 28, 2025, Adagio Medical Holdings announced a strategic restructuring to prioritize its FULCRUM-VT US pivotal IDE trial and product design optimization program. The restructuring includes a reduction in workforce and a pause in the European launch of the vCLAS catheter, allowing the company to focus on obtaining FDA premarket approval for its VT Cryoablation System. This move is expected to position Adagio as a leader in ventricular tachycardia solutions, a historically underserved market.
More about Adagio Medical Holdings
Adagio Medical Holdings, Inc. is an early commercial stage medical device company based in Laguna Hills, California. The company specializes in developing proprietary Ultra-Low Temperature Cryoablation technology aimed at treating cardiac arrhythmias, with a particular focus on ventricular tachycardia.
YTD Price Performance: 31.62%
Average Trading Volume: 494,618
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $23.69M
Learn more about ADGM stock on TipRanks’ Stock Analysis page.